Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Land Shark who wrote (20117)	3/12/1999 2:53:00 PM
From: Jetter	Read Replies (3) \| Respond to of 122087

ENMD... Am I the only one that absolutely cannot believe this crap keeps going up??? Honestly...

To: Land Shark who wrote (20117)	3/12/1999 2:57:00 PM
From: R Fish	Read Replies (1) \| Respond to of 122087

Does anybody else out there have the feeling that the daytraders don't want to hold PPOD, HEPH, IMOT, and others that ran for the past day and 1/2 over the weekend? I'll probably be like a CNBC analyst and be really wrong, but my gut says nobody wants to hold over the weekend. Looking for an eod sell off.

To: Land Shark who wrote (20117)	3/12/1999 3:28:00 PM
From: Wes Stevens	Read Replies (1) \| Respond to of 122087

Heph will present at a conference on the 24th. Could stay strong till then. Hollis-Eden to Present AIDS Primate Study Data At 12th International Conference for Antiviral Research PR Newswire, Monday, March 08, 1999 at 08:49 SAN DIEGO, March 8 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today that it will be presenting data at the 12th International Conference for Antiviral Research from an ongoing study using its lead drug candidate, HE2000, in a primate model infected with SHIV-229. SHIV-229 is a particularly virulent form of the simian AIDS virus. The conference will be held in Jerusalem, Israel from March 21 to March 25, 1999; the HE2000 presentation is currently scheduled for Wednesday, March 24. Researchers at the Northwestern Regional Primate Center at the University of Washington in Seattle conducted the study. HE2000 is believed to work by inhibiting the host cell's energy-producing enzymes and proteins, thereby "starving" the virus of the energy that it needs to replicate. This novel drug candidate, targeted for the treatment of HIV/AIDS, was discovered and developed by Dr. Patrick T. Prendergast at his research company, Colthurst Ltd., based in Europe. Hollis-Eden holds an exclusive worldwide license to HE2000. "We're gratified to be selected for an oral presentation at this world-class forum," said James Frincke, Ph.D., Executive Vice President of Research and Development at Hollis-Eden. "We will announce full details and data from the study at the time of the presentation." Hollis-Eden Pharmaceuticals, Inc. is a San Diego-based biopharmaceutical company engaged in the development and commercialization of products for the treatment of infectious diseases and immune system disorders. For more information about Hollis-Eden, contact the company's web site at holliseden.com. Statements made in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to successfully complete pivotal clinical trials, the Company's future capital needs, the Company's ability to obtain additional funding and required regulatory approvals, the development of competitive products by other companies, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. SOURCE Hollis-Eden Pharmaceuticals, Inc. -0- 03/08/99 /CONTACT: Melanie Guy of Russell-Welsh, Inc., 650-312-0700, ext. 2